Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 1, 2025

Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA

View original at globenewswire.com
Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA Dublin, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The buffer preparation market size is currently valued at USD 8.58 billion and is projected to reach 17.96 billion by 2035, growing at a CAGR of 7.8% during the forecast period

    80% confidence
  • The small molecules segment is likely to capture the maximum share (~75%) due to the extensive therapeutic potential of small molecules and the rising occurrence of chronic illnesses

    80% confidence
  • 86% of the buffer manufacturing systems are fabricated using stainless steel; 95% of the buffer systems work automatically with various controls for pH, conductivity, temperature and pressure

    80% confidence
  • Over 60% of the firms engaged in this domain manufacture custom buffers; most of these buffers have been formulated as liquid bottles

    80% confidence
  • The cell and gene therapies segment will grow at a significantly higher CAGR (19.5%) throughout the forecast period

    80% confidence
  • The antibodies segment is likely to capture the maximum share (~55%) of the overall market

    80% confidence
  • The bottles segment captures the majority share (~40%) in the overall market in the current year and is likely to dominate the market in the future

    80% confidence
  • Around 60 buffer manufacturing systems are currently available in the market for stabilizing drug components in biopharmaceuticals; notably, most of these buffer systems are offered by players based in the US

    80% confidence
  • More than 70 companies are offering buffer manufacturing services for different packaging formats; close to 55% of the buffer manufacturing service providers are based in North America

    80% confidence
  • Close to 20% of the total partnership deals have been signed in the last two years, showing growing stakeholder interest in buffer manufacturing

    80% confidence
  • The reusable buffer mixing / preparation equipment market segment is likely to capture the majority share (~80%) in the overall market in the current year and is likely to grow at a relatively faster rate during the forecast period

    80% confidence
  • The market in Asia-Pacific is likely to grow at a high CAGR (8%), during the forecast period

    80% confidence
  • The liquid formulations segment is likely to capture the maximum share (~70%) due to liquid buffers providing consistency between batches and minimizing the chance of human mistakes

    80% confidence
  • North America is likely to capture the majority share (~40%) in the overall market currently, and this trend is unlikely to change in the future

    80% confidence
  • The commercial scale segment is likely to capture the maximum share (~85%) and this trend is likely to remain the same in the coming years

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA — Source | Via News | ViaNews Market